Recursion Pharmaceuticals RXRX
NASDAQ RXRX
$4.07 -0.06 (-1.45%)
As of: Oct 1, 2026 · 3:59 PM EDT

Recursion Pharmaceuticals (RXRX) Cash from Financing Activities (2020 - 2026)

Updated

Recursion Pharmaceuticals' Cash from Financing Activities came in at -$1.27 million for Q2 2026, compared with $97.66 million a year earlier.

Analysis

Recursion Pharmaceuticals (RXRX) Cash from Financing Activities (2020 - 2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, Recursion Pharmaceuticals reported Cash from Financing Activities of $378.61 million, up 129.1% year-over-year; for FY2025, it came in at $521.53 million, up 71.5% from FY2024.

  • Cash from Financing Activities carries a five-year compound annual growth rate of 16.2% (FY2020 to FY2025).
  • Going back by year, Cash from Financing Activities was $304.12 million in FY2024 (+117.0%), $140.13 million in FY2023 (-9.2%), $154.35 million in FY2022 (-66.3%) and $458.54 million in FY2021 (+86.3%).
  • The five-year range for quarterly Cash from Financing Activities is -$11.1 million (Q3 2021) to $263.12 million (Q2 2024).
  • Year-over-year, Cash from Financing Activities increased in 1 of the last four quarters, with an average decline of 6.9%.
  • The fastest year-over-year change in Cash from Financing Activities over five years came in Q1 2024 (growth of 623.0%), and the weakest in Q2 2022 (a decline of 99.4%).
  • Business Quant data shows RXRX's Cash from Financing Activities at -$3.47 million (Q1 2026), $132.01 million (Q4 2025) and $251.34 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -8.78 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -5.05 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 1.76 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -2.02 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -47.00 Mn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -1.48 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 2.34 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -3.66 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -426.70 Mn
10 Recursion Pharmaceuticals 2.21 Bn -397.37 Mn -3.82 Mn -1.27 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -1.27 Mn
Mar 31, 2026 -3.47 Mn
Dec 31, 2025 132.01 Mn
Sep 30, 2025 251.34 Mn
Jun 30, 2025 97.66 Mn
Mar 31, 2025 40.53 Mn
Dec 31, 2024 10.64 Mn
Sep 30, 2024 16.46 Mn
Jun 30, 2024 263.12 Mn
Mar 31, 2024 13.90 Mn
Dec 31, 2023 80.66 Mn
Sep 30, 2023 53.77 Mn
Jun 30, 2023 3.79 Mn
Mar 31, 2023 1.92 Mn
Dec 31, 2022 147.26 Mn
Sep 30, 2022 2.34 Mn
Jun 30, 2022 2.67 Mn
Mar 31, 2022 2.08 Mn
Dec 31, 2021 3.80 Mn
Sep 30, 2021 -11.10 Mn
API Access

Recursion Pharmaceuticals Cash from Financing Activities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-financing-activities&ticker=RXRX&period=max&api_key=YOUR_API_KEY